Mendelsohn shares Tang Prize for leadership in developing targeted therapy
Targeted cancer therapy pioneer John Mendelsohn, M.D., researcher and former president of The University of Texas MD Anderson Cancer Center, will share the 2018 Tang Prize in Biopharmaceutical Science for his leadership in developing antibodies to block cancer-promoting growth factor receptors on the surface of cancer cells.
In announcing the award on June 19 in Taiwan, the Tang Foundation noted the three awardees launched the...
Phase III study shows quizartinib prolongs overall survival for patients with deadly type of relapsed or refractory AML
A study led by The University of Texas MD Anderson Cancer Center revealed that the investigational drug quizartinib prolonged overall survival...
Researchers find combination can enhance ipilimumab immunotherapy
Using a targeted therapy to block a protein that suppresses T cell activity could improve cancer treatment with immune checkpoint inhibitors...
MD Anderson, Houston Methodist scientists detect new ovarian cancer target
Researchers at Houston Methodist Research Institute and The University of Texas MD Anderson Cancer Center have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer.
Their preclinical research, reported in the Journal of the National Cancer Institute, integrated computational modeling...
Aspen Making Cancer History® Seminar marks 20th anniversary
The University of Texas MD Anderson Cancer Center will host its 20th annual Making Cancer History® seminar in Aspen, 10 a.m.-12 p.m. Monday...
PARP inhibitor improves overall response rates in small cell lung cancer patients
In a randomized, Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center adding the PARP inhibitor veliparib...
MD Anderson Therapeutics Discovery team identifies and advances a drug that targets metabolic vulnerability and impairs cancer cell growth and survival
A drug discovered and advanced by The University of Texas MD Anderson Cancer Center’s Institute for Applied Cancer Science (IACS) and TRACTION...
MD Anderson and nation’s top cancer centers endorse goal of eliminating HPV-related cancers
Recognizing that vaccination rates for the human papillomavirus (HPV) remain low across the U.S., particularly in Texas, The University of...
MD Anderson announces 2018 Andrew Sabin Family Fellows
The University of Texas MD Anderson Cancer Center has named eight researchers to the third annual class of Andrew Sabin Family Fellows. As...
Checkpoint inhibitor shrinks advanced squamous cell skin cancer
Clinical trials show that an immune checkpoint inhibitor shrinks the tumors of nearly half of patients with an incurable, advanced form of...